ZEBINIX
Trade name:
ZEBINIX 800 mg N30 tablets
Cod ATC:
N03AF04
Active substance:
Dosage:
Manufacturer
BIAL – Portela & Cª À Avenida da Siderurgia Nacional, 4745-457 Coronado (S. Romão e S. Mamede), Portugalia
Therapeutic indications:
- Monotherapy for the treatment of partial onset seizures with, with or without secondary generalization in patients with newly diagnosed epilepsy
- Adjuvant therapy for adults, adolescents, and children over 6 years of age with partial onset seizures with or without secondary generalization
Description:
ZEBINIX is an innovative medicine with a different mechanism of action than other sodium channel blockers. It is an effective alternative to adjuvant treatment and monotherapy in patients with partial (focal) seizures with or without secondary generalization.
It combines long-term clinical efficacy with a good tolerability profile and a easy way of of administration.
It reduces the frequency of seizures in 81.8% of patients after 6 months from starting the treatment.
Pharmacovigilance
Information about drug safety
Pharmacovigilance is the science and activities related to the detection, evaluation, understanding and prevention of adverse effects or any other problem related to medicines.
